Aligos planning for Phase 2 trial of treatment for hepatitis B
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1 drug-drug interaction study to evaluate the effects of certain drugs…
News
RTY-694 chosen as lead treatment candidate for liver disease PSC
Rectify Pharmaceuticals has selected the oral small molecule RTY-694 as its lead treatment candidate for primary sclerosing cholangitis (PSC) and plans are underway…
Early-onset pregnancy cholestasis increases risk of diabetes: Study
Women diagnosed with intrahepatic cholestasis of pregnancy (ICP) before 24 weeks of gestation, or about six months, are significantly more likely to develop gestational…
Study fully enrolled of Rezdiffra for well-compensated liver cirrhosis
A Phase 3 clinical trial testing Rezdiffra (resmetirom) in people with well-compensated cirrhosis, or irreversible liver scarring that still allows the liver to work, due…
Protein in blood may be liver scarring marker in biliary atresia
Higher levels of a protein called amyloid precursor protein (APP) in the blood may be a marker of fibrosis, or liver scarring, in biliary…
Zetomipzomib found safe in Phase 2a trial for autoimmune hepatitis
The safety monitoring committee of a Phase 2a clinical trial testing zetomipzomib in people with autoimmune hepatitis has found no major safety issues with…
Full approval on Ocaliva for primary biliary cholangitis delayed
The U.S. Food and Drug Administration (FDA) is still reviewing Intercept Pharmaceuticals’ application for full approval of Ocaliva (obeticholic acid) as a second-line…
Excessive copper in PFIC3 may lead to misdiagnosis: Case report
Excessive copper levels in the body led to an initial misdiagnosis of Wilson disease, a rare condition marked by copper buildup in the liver and…
Therapy to silence SPTBN1 protein eases liver fat, scarring in mice
Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of two forms of fatty…
New study may explain milder liver scarring seen in Alagille syndrome
Alterations to the immune system may underlie the mild liver scarring, or fibrosis, that characterizes Alagille syndrome despite severe liver disease, according to a…
Recent Posts
- Biliary atresia patient spotlighted in 2025 ALF Liver Life Walk
- How I advocated for my brother before and after his PSC diagnosis
- Researchers uncover how hepatitis B virus can persist in liver cells
- CM-101 (nebokitug) set for primary sclerosing cholangitis Phase 3 trial
- Researchers develop tool to predict drug-induced cholestasis